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The basis of the analysis of the clinical study (intention to treat or treatment completers) was not stated. The primary health outcomes were the number of hospitalisations, the length of hospital stay and New York Heart Association (NYHA) functional class.
Effectiveness results
Compared to the control period, the study period (3.9 +/-2.7 months) was associated with a reduction in the number of hospital admissions from 2.7 (+/-2.6) to 1.3 (+/-1.3), (p=0.056), and length of hospital stay from 20.9 (+/-12.7) to 5.5 (+/-5.4) days, (p=0.0004). NYHA functional class also improved from 4.0 (+/-0.0) to 2.7 (+/-0.9), (p<0.0001), in the study period.
Clinical conclusions
Home IV inotropic therapy reduced hospital admissions, and length of stay and improved functional class in patients with advanced heart failure.
Measure of benefits used in the economic analysis
No summary benefit measure was derived from the effectiveness results. As such the benefits are assumed to be equal to the effectiveness outcomes. (Note: the authors defined the control period as the time interval immediately preceding the institution of HIIT and equal in length to the study period which is defined as the interval during which the subjects receive HIIT.)A home health nurse interviewed and educated subjects about the proposed therapy.
Direct costs
Direct costs included in-patient, out-patient (laboratory tests, clinic visits, etc.), and home health care costs. No discounting was stated (as the study ran for less than 1 year). Quantities and costs were not analysed separately.
Currency

US dollars ($).
Sensitivity analysis
No sensitivity analysis was performed.
Estimated benefits used in the economic analysis
Compared to the control period, the study period (3.9 +/-2.7 months) was associated with a reduction in the number of hospital admissions from 2.7 (+/-2.6) to 1.3 (+/-1.3), (p=0.056), and length of hospital stay from 20.9 (+/-12.7) to 5.5 (+/-5.4) days, (p=0.0004). New York Heart Association (NYHA) functional class also improved from 4.0 (+/-0.0) to 2.7 (+/-0.9), (p<0.0001), in the study period. Eight subjects (33%) died after 2.8 (+/-1.7) months of HIIT.
Cost results
Total intervention costs were not calculated for the project as a whole.
Synthesis of costs and benefits
A 16% reduction in costs for the study period compared with the control period was found, saving $5,700 per client ($1,465 per client per month).
